Imuprin (Azathioprine)

Azathioprine is a prodrug that is converted inside cells to 6‑mercaptopurine. This metabolite blocks the synthesis of purine nucleotides, which are essential building blocks for DNA and RNA. By limiting purine production, the drug reduces the proliferation of lymphocytes, thereby suppressing both cellular and humoral immunity.

The dosage of Imuprin is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and laboratory monitoring results. Physicians determine the appropriate starting dose and any subsequent adjustments during treatment.

The safety of azathioprine in pregnancy and lactation is not fully established, and it is classified as a drug with unknown pregnancy category. Healthcare providers must weigh potential benefits against possible risks and discuss these considerations with the patient before initiating therapy.

To request Imuprin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both azathioprine (Imuprin) and mycophenolate mofetil are antimetabolite immunosuppressants that inhibit lymphocyte proliferation, but they act on different enzymes in the purine synthesis pathway. Azathioprine is converted to 6‑mercaptopurine, whereas mycophenolate blocks inosine monophosphate dehydrogenase. Choice between them depends on the clinical scenario, side‑effect profile, and physician preference.

Imuprin tablets should be stored at ambient temperature, below 25 °C, in their original container. The packaging protects the product from moisture and light, helping to maintain potency throughout its shelf life.

Imuprin is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule—once daily or divided doses—is determined by the treating physician according to the patient’s condition and response to therapy.

The most critical adverse effects include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity that may progress to liver failure, and an increased susceptibility to opportunistic infections. Patients should be monitored regularly for blood count abnormalities and liver enzyme changes.

Imuprin is contraindicated in individuals with known hypersensitivity to azathioprine or its metabolites, in patients with active severe infections, and in those who have received live vaccines within a short period before starting therapy. Caution is also advised for patients with significant hepatic or renal impairment.